Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024 [1] - Among the 38 listed medical device companies, the average annual salary of CFOs is 908,600 yuan [1] - The age distribution of CFOs shows that those aged 40-50 constitute 57%, while those over 50 account for 32% [1] Group 2 - The educational background of CFOs indicates that 66% hold a bachelor's degree, while only 2% have a doctoral degree [1] - The top three highest-paid CFOs in the medical device sector are Dai Zhenhua from Huatai Medical, Rui Chen from Nanwei Medical, and Wu Jinhong from Guoke Hengtai, with salaries of 2.70 million yuan, 2.65 million yuan, and 1.77 million yuan respectively [1] - The largest salary decrease was observed for Kong Xiangqian from Aidi Te, with a year-on-year decline of 16.86%, while Song Yizhao from Shandong Pharmaceutical Glass saw the largest increase at 144.86% [1]

Core Insights - The report highlights the significant role of CFOs in listed companies, with the total compensation for A-share CFOs reaching 4.27 billion yuan in 2024, averaging 814,800 yuan per year [1][2] Group 1: CFO Compensation Overview - The average annual salary for CFOs in the A-share medical device sector is 908,600 yuan [2] - The distribution of CFO salaries shows that 24% earn below 500,000 yuan, 42% earn between 500,000 and 1 million yuan, 29% earn between 1 million and 2 million yuan, and 5% earn above 2 million yuan [2] - The top three highest-paid CFOs are Dai Zhenhua from Huatai Medical at 2.70 million yuan, Rui Chenwei from Nanwei Medical at 2.65 million yuan, and Wu Jinhong from Guoke Hengtai at 1.77 million yuan [2] Group 2: CFO Demographics - The age distribution of CFOs shows that those aged 40-50 make up 57%, while 32% are over 50, and 11% are 40 or younger [1] - The youngest CFO is 31 years old, while the oldest is 60 years old [1] - In terms of educational background, 16% of CFOs have an associate degree, 66% hold a bachelor's degree, 16% have a master's degree, and only 2% possess a doctoral degree [1] Group 3: Salary Changes - Among CFOs with over two years of tenure, the largest salary decrease was observed for Kong Xiangqian from Aidi Te, with a decline of 16.86% year-on-year [2] - Conversely, the largest salary increase was for Song Yizhao from Shandong Glass, with a rise of 144.86% year-on-year [2]

Core Insights - The report highlights the significant role and compensation of CFOs in A-share listed companies, with a total salary scale of 4.27 billion yuan and an average annual salary of 814,800 yuan for CFOs in 2024 [1][2] Group 1: CFO Compensation Overview - The average annual salary for CFOs in the medical device sector of A-shares is 908,600 yuan [2] - The distribution of CFO salaries shows that 24% earn below 500,000 yuan, 42% earn between 500,000 and 1 million yuan, 29% earn between 1 million and 2 million yuan, and 5% earn above 2 million yuan [2] - The top three highest-paid CFOs are Dai Zhenhua from Huatai Medical at 2.70 million yuan, Rui Chenwei from Nanwei Medical at 2.65 million yuan, and Wu Jinhong from Guoke Hengtai at 1.77 million yuan [2] Group 2: CFO Demographics - The age distribution of CFOs indicates that those aged 40-50 constitute 57%, while 32% are over 50, and 11% are 40 or younger [1] - The youngest CFO is 31 years old, Shao Kejie from Tianyi Medical, while the oldest is 60 years old, Xiang Qinhua from Nanwei Co., Ltd. [1] - In terms of educational background, 16% of CFOs have an associate degree, 66% hold a bachelor's degree, 16% have a master's degree, and only 2% possess a doctoral degree, with only one CFO holding a PhD [1]

Core Insights - The report highlights the significant role of CFOs in listed companies, with the total salary scale for A-share CFOs reaching 4.27 billion yuan in 2024, averaging 814,800 yuan per year [1][2] Salary Distribution - The average annual salary for CFOs in the A-share medical device sector is 908,600 yuan, with 24% earning below 500,000 yuan, 42% between 500,000 and 1 million yuan, 29% between 1 million and 2 million yuan, and 5% earning above 2 million yuan [2] - The top three highest-paid CFOs are Dai Zhenhua from Huatai Medical at 2.70 million yuan, Rui Chenwei from Nanwei Medical at 2.65 million yuan, and Wu Jinhong from Guoke Hengtai at 1.77 million yuan [2] CFO Age Distribution - CFOs aged 40-50 constitute 57% of the market, while those over 50 account for 32%, and those 40 and below make up 11%. The youngest CFO is 31 years old, and the oldest is 60 years old [1] CFO Educational Background - The educational background of CFOs shows that 16% have an associate degree, 66% hold a bachelor's degree, 16% have a master's degree, and only 2% possess a doctoral degree, with only one CFO holding a PhD [1]

Core Insights - The DRG/DIP concept increased by 1.00%, ranking 10th among concept sectors, with 11 stocks rising, including Jiarun Technology which hit a 20% limit up [1] - Major gainers in the sector included Jiahe Meikang, Wanda Information, and Taiji Co., with respective increases of 3.68%, 3.08%, and 2.98% [1] - The sector experienced a net outflow of 229 million yuan, with 10 stocks seeing net inflows, and Wanda Information leading with a net inflow of 65.92 million yuan [2][3] Sector Performance - The top-performing concept sectors included Rare Earth Permanent Magnet (+3.24%), Brain-Computer Interface (+2.69%), and Hyperbaric Oxygen Chamber (+2.56%), while the weight-loss drug sector saw a decline of -1.70% [2] - The DRG/DIP concept had a net inflow ratio led by Wanda Information at 10.09%, followed by ST Yilianzhong at 5.78% and Taiji Co. at 4.82% [3][4] Stock Specifics - Key stocks in the DRG/DIP concept included: - Wanda Information: +3.08%, net inflow of 65.92 million yuan, turnover rate of 5.34% [3] - Weining Health: +1.72%, net inflow of 62.81 million yuan, turnover rate of 6.37% [3] - Taiji Co.: +2.98%, net inflow of 42.14 million yuan, turnover rate of 5.36% [3] - Notable declines were seen in stocks like Maidi Technology (-2.61%) and Seli Medical (-2.32%), with significant net outflows [4]

Company Overview - As of August 6, 2025, Guoke Hengtai's stock price is 11.36 yuan, down 0.05 yuan or 0.44% from the previous trading day [1] - The company operates in the trade industry, focusing on medical device supply chain services, headquartered in Beijing [1] Legal Issues - Guoke Hengtai and its subsidiaries have been involved in 42 lawsuits and arbitrations over the past 12 months, with a total amount in dispute of 343 million yuan, representing 13.84% of the company's latest audited net assets [1] - The company is the plaintiff in 96.50% of these cases, with a disputed amount of 331 million yuan, while it is the defendant in 3.50% of the cases, amounting to 1.2037 million yuan [1] - Some cases are still pending trial or judgment, leading to uncertainty regarding their impact on the company's profits [1] Financial Performance - In 2024, Guoke Hengtai's net profit decreased by 15.09% year-on-year [1] - In the first quarter of 2025, the company reported a loss of 8.95 million yuan [1] Market Activity - On August 6, 2025, the net outflow of main funds from Guoke Hengtai was 667,500 yuan, with a cumulative net outflow of 28.0347 million yuan over the past five days [1]

关于累计诉讼、仲裁情况的公告 证券代码：301370 证券简称：国科恒泰 公告编号：2025-049 国科恒泰（北京）医疗科技股份有限公司 二、其他尚未披露的诉讼、仲裁事项 截至本公告披露日，公司不存在应披露而未披露的其他重大诉讼、仲裁事项。 三、本次公告的诉讼、仲裁事项对公司本期利润或期后利润的可能影响 对于公司涉及的诉讼、仲裁案件，公司将积极应诉，妥善处理，依法保护公 司及广大投资者的合法权益。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据《深圳证券交易所创业板股票上市规则》第 8.7.3 条规定，国科恒泰（北 京）医疗科技股份有限公司（以下简称"公司"）对公司及合并报表范围内的子 公司连续十二个月内累计涉及诉讼、仲裁事项进行了统计，涉及金额累计达到信 息披露标准。现将有关情况公告如下： 一、累计诉讼、仲裁事项基本情况 截至本公告披露日，公司及合并报表范围内的子公司连续十二个月内累计发 生的诉讼、仲裁共 42 起，涉案金额合计 34,283.17 万元，占公司最近一期经审计 净资产的 13.84%。 其中，公司及合并报表范围内的子公司作为原告的诉讼 ...

Group 1 - The company, Guoke Hengtai (Beijing) Medical Technology Co., Ltd., held a second extraordinary general meeting in 2025, where the proposal to amend the Articles of Association was approved [1] - The specific details of the amendment to the Articles of Association were disclosed on June 24, 2025, on the Giant Tide Information Network [1] - The company has completed the filing and registration procedures for the amended Articles of Association with the Market Supervision Administration of Beijing Economic and Technological Development Zone [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：301370 证券简称：国科恒泰 公告编号：2025-048 国科恒泰（北京）医疗科技股份有限公司 关于完成《公司章程》备案登记的公告 国科恒泰（北京）医疗科技股份有限公司（以下简称"公司"）于 2025 年 6 月 23 日召开第三届董事会第四十次会议，于 2025 年 7 月 9 日召开 2025 年第 二次临时股东大会，审议通过了《关于修订<公司章程>的议案》。具体内容详见 公司于 2025 年 6 月 24 日在巨潮资讯网披露的《公司章程》、《关于修订<公司 章程>的公告》（公告编号：2025-035）。 近日，公司在北京经济技术开发区市场监督管理局完成了《公司章程》的备 案登记手续。 特此公告。 2025 年 7 月 31 日 国科恒泰（北京）医疗科技股份有限公司 董事会 ...

一、董事会会议召开情况 事会第四十二次会议已于 2025 年 7 月 17 日通过电子邮件方式通知了全体董事。 席董事 9 名（其中董事刘冰、肖薇以现场方式参加会议，其他董事以通讯方式参 加会议）。公司监事及高级管理人员列席了本次会议。 等法律、法规及《公司章程》的有关规定，合法有效。 经与会董事认真审议，充分讨论，审慎表决，会议审议通过了以下议案： 证券代码：301370 证券简称：国科恒泰 公告编号：2025-045 国科恒泰（北京）医疗科技股份有限公司 公司独立董事张金鑫已向董事会提交辞职报告，其因个人工作安排申请辞去 公司独立董事职务，同时不再担任公司第三届董事会审计委员会主任委员、薪酬 与考核委员会委员、提名委员会委员，其原定任期至 2025 年 12 月 11 日，辞职 后不再担任公司任何职务。 张金鑫先生的辞职将导致公司独立董事人数少于董事会总人数的三分之一， 导致董事会专门委员会中独立董事所占比例不符合法律法规及《公司章程》的规 定，且缺少会计专业人士。根据《中华人民共和国公司法》《上市公司独立董事 管理办法》《公司章程》等有关规定，张金鑫先生的辞职报告将在公司补选新任 独立董事后生效。在此期 ...